Serge Saxonov - 10 Nov 2026 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

SEC form
4
Accepted by SEC
13 Nov 2026, 16:53:32 UTC
Prior SEC filing
24 Sep 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Serge Saxonov filed Form 4 for 10x Genomics, Inc. (TXG) on 13 Nov 2026.

Key facts

  • This page summarizes Serge Saxonov's Form 4 filing for 10x Genomics, Inc. (TXG).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2026, 16:53.

Change

  • Previous filing in this sequence was filed on 24 Sep 2026.
  • Current net transaction value: -$1,949,900.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001786720 Primary reporting owner

Saxonov Serge

Relationship
Chief Executive Officer, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXG transaction

Class A Common Stock

Sale

Transaction value
-$1,949,900
Shares
-31,000
Change %
-3%
Price
$62.90
Shares after
1,019,249
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1
TXG holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
27
Date
10 Nov 2026
Ownership
See footnote
Footnotes
F2
TXG holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
213,250
Date
10 Nov 2026
Ownership
See footnote
Footnotes
F3
TXG holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
71,644
Date
10 Nov 2026
Ownership
See footnote
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Reporting Person contributed the shares to an exchange fund in exchange for shares of the exchange fund. The shares were valued at $62.90 per share for the purpose of determining the number of shares of the exchange fund issuable to the Reporting Person.

Footnote F2

The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

Footnote F3

The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

Footnote F4

The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .